Connect
MJA
MJA

In This Issue

Ruth Armstrong
Med J Aust 2009; 190 (3): 106.
Published online: 2 February 2009

Proton-pump inhibitors not risk free

Patients taking proton-pump inhibitors (PPIs) are at a small but significantly increased risk of hospitalisation for pneumonia, say Roughead et al after examining war veterans’ health records over 5 years (→ Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia). The records revealed about 14 000 admissions for pneumonia among almost 200 000 veterans: those exposed to PPIs had a rate ratio of 1.16 (95% CI, 1.11-1.22) compared with those not exposed. While the increase in risk is small, the overall effect may be large because of the large numbers of people taking PPIs — about 1 million prescriptions in Australia per year. In “Risks of proton-pump inhibitors: what every doctor should know”, Talley points out that no drug is risk free and adds enteric infections, osteoporosis, vitamin B12 deficiency and interstitial nephritis to the list of conditions with which PPIs have been associated, repeating the useful maxim, “lowest dose for the shortest time . . .”

Kids and cholesterol

New guidelines released in the United States last year for managing lipid abnormalities in children caused ripples around the world. Were they really advocating widespread testing and drug therapy for kids as young as 8 years? In “Lipid abnormalities in children: should we be doing more?”, Ayer et al outline the changes to the guidelines and ask whether Australia should follow suit. In the sense of bringing all the experts together to estimate the extent of the problem and develop relevant local guidelines, yes indeed!

Childhood obesity: calling for sanity

If you follow it in the media, the commentary surrounding childhood obesity is a bit like the diary of a yo-yo dieter. One day our portly paediatric population is destined to a life of chronic disease and an early death, and the next the whole problem is in the imaginations of a few over-anxious public health advocates. But the problem is real, say Gill et al, and we need to get on with developing strategies, including a whole-of-population approach, to tackle it (→ Childhood obesity in Australia remains a widespread health concern that warrants population-wide prevention programs).

One of the factors fuelling confusion about childhood obesity is the lack of good data. According to Stubbs and Achat (→ Individual rights over public good? The future of anthropometric monitoring of school children in the fight against obesity), inconsistencies between study methods and the need for written parental consent have caused real problems with the quality of the available information. They argue that ongoing anthropometric monitoring of school children might be best achieved by an “opt-out” system in which all children participate unless they or their parents indicate otherwise.

If routine weight monitoring of kids puts a blip on your ethical radar, how about calling in the child protection authorities when parents badly neglect their children’s weight problems? In “When does severe childhood obesity become a child protection issue?”, Alexander et al present the case of an obese child whose physical and psychological decline prompted such action. Both medical and child protection authorities could do with some guidelines to cover these sorts of scenarios which, although rare, present real challenges.

In letters . . .

This issue’s Letters run to quite a few pages but are well worth the read. For an added layer of protection in your surgical gloves, for instance, you may wish to heed Turner’s advice (→ Povidone-iodine (Betadine) solution: a simple protectant in surgical gloves) or, if you’re a connoisseur of unusual cases, read Tran and Reeves’ account of a patient’s fortuitous response to immunoglobulin therapy (→ Treatment of type B insulin resistance with immunoglobulin: novel use of an old therapy).

Australia performing well in childhood stem cell transplantation

An increase in the use of non-related donors, a growing role for umbilical cord blood, a trend towards decreasing treatment-related mortality, and results broadly similar to those from overseas: these are some of the findings in a report from the Australasian Bone Marrow Transplant Recipient Registry. The registry collects data from all hospitals in Australia and New Zealand in which haemopoietic stem cell transplantation (HSCT) is performed. Relapse of the underlying condition remains the major cause of mortality conclude Moore et al (→ Haemopoietic stem cell transplantation for children in Australia and New Zealand, 1998-2006: a report on behalf of the Australasian Bone Marrow Transplant Recipient Registry and the Australian and New Zealand Children’s Haematology Oncology Group), but HSCT offers the best chance of cure to many children with otherwise fatal conditions.

Drug dose calculations: try this quick quiz

Most doctors have never been assessed for their ability to calculate drug doses, and do not meet their own standards for accuracy in such calculations. These findings emerged when Simpson et al administered a 12-item test to 190 doctors working in a Queensland teaching hospital (→ A survey of drug-dose calculation skills of Australian tertiary hospital doctors). Senior staff and those working in the critical care specialties did better than other doctors. How would you have scored?

Another time . . . another place

The level of civilization attained by any society will be determined by the attention it has paid to the welfare of its children.

Billy F Andrews, 1968

 

 

  • Ruth Armstrong


Correspondence: 

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.